502 related articles for article (PubMed ID: 30798468)
1. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
2. Update on adrenocortical carcinoma management and future directions.
Varghese J; Habra MA
Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):208-214. PubMed ID: 28277340
[TBL] [Abstract][Full Text] [Related]
3. Current Status and Future Targeted Therapy in Adrenocortical Cancer.
Alyateem G; Nilubol N
Front Endocrinol (Lausanne); 2021; 12():613248. PubMed ID: 33732213
[TBL] [Abstract][Full Text] [Related]
4. Adrenocortical carcinoma: the management of metastatic disease.
Fay AP; Elfiky A; Teló GH; McKay RR; Kaymakcalan M; Nguyen PL; Vaidya A; Ruan DT; Bellmunt J; Choueiri TK
Crit Rev Oncol Hematol; 2014 Nov; 92(2):123-32. PubMed ID: 24958272
[TBL] [Abstract][Full Text] [Related]
5. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
6. Surgical management of adrenocortical carcinoma.
Ranvier GG; Inabnet WB
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
Habra MA; Stephen B; Campbell M; Hess K; Tapia C; Xu M; Rodon Ahnert J; Jimenez C; Lee JE; Perrier ND; Boraddus RR; Pant S; Subbiah V; Hong DS; Zarifa A; Fu S; Karp DD; Meric-Bernstam F; Naing A
J Immunother Cancer; 2019 Sep; 7(1):253. PubMed ID: 31533818
[TBL] [Abstract][Full Text] [Related]
8. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for adrenocortical carcinoma.
Berruti A; Ferrero A; Sperone P; Daffara F; Reimondo G; Papotti M; Dogliotti L; Angeli A; Terzolo M
Expert Opin Emerg Drugs; 2008 Sep; 13(3):497-509. PubMed ID: 18764725
[TBL] [Abstract][Full Text] [Related]
10. Conventional chemotherapy and emerging targeted therapy for advanced adrenocortical carcinoma.
Xu YZ; Zhu Y
Anticancer Agents Med Chem; 2013 Feb; 13(2):248-53. PubMed ID: 22934700
[TBL] [Abstract][Full Text] [Related]
11. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
El Ghorayeb N; Rondeau G; Latour M; Cohade C; Olney H; Lacroix A; Perrotte P; Sabourin A; Mazzuco TL; Bourdeau I
Medicine (Baltimore); 2016 Mar; 95(13):e3180. PubMed ID: 27043680
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for the treatment of adrenocortical carcinoma.
Sukrithan V; Husain M; Kirschner L; Shah MH; Konda B
Expert Opin Emerg Drugs; 2021 Jun; 26(2):165-178. PubMed ID: 33896321
[No Abstract] [Full Text] [Related]
13. New targeted therapies for adrenocortical carcinomas.
Manso J; Pezzani R
Minerva Endocrinol; 2019 Mar; 44(1):70-81. PubMed ID: 29808641
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers and targeted therapies for adrenocortical carcinoma.
Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
[TBL] [Abstract][Full Text] [Related]
15. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
16. New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review).
Stigliano A; Cerquetti L; Lardo P; Petrangeli E; Toscano V
Oncol Rep; 2017 Mar; 37(3):1301-1311. PubMed ID: 28184938
[TBL] [Abstract][Full Text] [Related]
17. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
18. 5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.
Hoff AO; Berruti A
Horm Cancer; 2016 Feb; 7(1):29-35. PubMed ID: 26728470
[TBL] [Abstract][Full Text] [Related]
19. 5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.
Rao SN; Habra MA
Horm Cancer; 2016 Feb; 7(1):17-23. PubMed ID: 26660146
[TBL] [Abstract][Full Text] [Related]
20. Long-term complete remission of metastatic adrenocortical carcinoma.
Cárdenas-Salas J; Castelo B; Regojo RM; González-Sanchez JA; Álvarez-Escolá C
Horm Mol Biol Clin Investig; 2023 Mar; 44(1):67-71. PubMed ID: 36069780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]